Wedbush Has Negative Forecast for BCRX FY2026 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Stock analysts at Wedbush dropped their FY2026 earnings per share estimates for BioCryst Pharmaceuticals in a research report issued to clients and investors on Wednesday, October 15th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings per share of $0.47 for the year, down from their prior forecast of $0.80. Wedbush has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q4 2026 earnings at $0.13 EPS, FY2027 earnings at $0.56 EPS and FY2029 earnings at $1.85 EPS.

BCRX has been the subject of a number of other reports. Cantor Fitzgerald lifted their price objective on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an "overweight" rating in a research report on Wednesday. Royal Bank Of Canada restated an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Bank of America boosted their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday, July 1st. Needham & Company LLC boosted their target price on BioCryst Pharmaceuticals from $17.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $19.18.

BioCryst Pharmaceuticals Stock Down 1.3%

Shares of BCRX stock opened at $6.72 on Friday. The stock has a 50-day moving average price of $7.87 and a 200 day moving average price of $8.64. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -37.33, a PEG ratio of 1.43 and a beta of 1.05. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. BioCryst Pharmaceuticals's revenue for the quarter was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.06) earnings per share.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares in the company, valued at $556,145.52. The trade was a 51.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently modified their holdings of BCRX. Allianz Asset Management GmbH increased its holdings in shares of BioCryst Pharmaceuticals by 9.6% during the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock worth $103,000 after acquiring an additional 1,200 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in BioCryst Pharmaceuticals by 7.7% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company's stock valued at $161,000 after buying an additional 1,288 shares in the last quarter. Royal Bank of Canada grew its holdings in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock valued at $476,000 after buying an additional 1,458 shares in the last quarter. Captrust Financial Advisors grew its holdings in BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company's stock valued at $198,000 after buying an additional 1,527 shares in the last quarter. Finally, Main Management ETF Advisors LLC grew its holdings in BioCryst Pharmaceuticals by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company's stock valued at $1,005,000 after buying an additional 1,824 shares in the last quarter. Institutional investors own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.